食品与发酵工业 >

2024 , Vol. 50 >Issue 19: 56 - 62

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.037739

研究报告

体外降糖降脂益生菌筛选及复配益生菌活性探究

  • 闫梦晴 ,
  • 郑彦懿 ,
  • 张璐 ,
  • 柳嘉 ,
  • 蓝彩娟 ,
  • 周晓莉 ,
  • 曾雪莹 ,
  • 张思璐 ,
  • 刘国玉
展开
  • 1(中国食品发酵工业研究院有限公司,功能主食创制与慢病营养干预北京市重点实验室,北京,100015)
    2(深圳保时健生物工程有限公司,深圳,518000)
第一作者:硕士研究生(刘国玉工程师和张思璐工程师为共同通信作者,E-mail:lgy17091037820@163.com;echo.zhang@wonderlab.top)

收稿日期: 2023-10-24

  修回日期: 2023-12-22

  网络出版日期: 2024-10-29

基金资助

中轻集团科技创新基金项目(ZQ2022YY02)

收起

Screening of glucose-lowering and lipid-lowering probiotics in vitro and exploration of the activity of compound probiotics

  • YAN Mengqing ,
  • ZHENG Yanyi ,
  • ZHANG Lu ,
  • LIU Jia ,
  • LAN Caijuan ,
  • ZHOU Xiaoli ,
  • ZENG Xueying ,
  • ZHANG Silu ,
  • LIU Guoyu
Expand
  • 1(China National Research Institute of Food and Fermentation Industries Co.LTD., Beijing Key Laboratory of the Innovative Development of Functional Staple and Nutritional Intervention for Chronic Diseases, Beijing 100015, China)
    2(Shenzhen Precision Health Food Technology Co.Ltd., Shenzhen 518000, China)

Received date: 2023-10-24

  Revised date: 2023-12-22

  Online published: 2024-10-29

Fold

摘要

为获得到降糖降脂综合能力较佳的复配益生菌,该研究以8种常用益生菌为研究对象,测定其体外降糖能力、胆固醇清除率、胃肠道耐受性及其他性能。以所测指标为因子,通过主成分分析方法筛选出综合能力较优的菌株,并进行菌株间拮抗分析及复配益生菌较佳比例的探究。此外,对较佳比例的复配益生菌进行益生元嗜好性分析。结果表明,植物乳杆菌CFFM1031和乳双歧杆菌CFFM2012降糖降脂综合能力较优,2种菌株之间无拮抗作用,与单一菌株或其他比例复配菌株相比,1:1比例复配的菌株具有显著的胆固醇清除能力(43.56%),且复配益生菌在低聚半乳糖或水苏糖为碳源时增殖能力较强,表现出嗜好性。该研究可为益生菌协同增效研究及功能食品配方的开发提供参考。

关键词： 益生菌; 降糖降脂能力; 拮抗分析; 复配益生菌; 促增殖

本文引用格式

闫梦晴 , 郑彦懿 , 张璐 , 柳嘉 , 蓝彩娟 , 周晓莉 , 曾雪莹 , 张思璐 , 刘国玉 . 体外降糖降脂益生菌筛选及复配益生菌活性探究[J]. 食品与发酵工业, 2024 , 50(19) : 56 -62 . DOI: 10.13995/j.cnki.11-1802/ts.037739

Abstract

In order to obtain a compound probiotic with a better comprehensive ability to lower blood glucose and lipid levels, this study tested the effectiveness of eight commonly available probiotics in blood glucose lowering abilities, cholesterol clearance, gastrointestinal tolerance, and other activities in vitro.Principal component analysis was used to screen out strains with better comprehensive ability by taking the measured indicators as factors.Antagonism analysis was then performed among the strains, and the optimal proportion of compound probiotics was also determined.Additionally, a preference analysis for prebiotics was performed on the compound probiotic.The results showed that Lactobacillus plantarum CFFM1031 and Bifidobacterium lactis CFFM2012 were the most effective strains in reducing blood glucose and lipid levels.No antagonistic effect was observed between these two strains.The study found that a compound with a 1:1 ratio of L.plantarum CFFM1031 and B.lactis CFFM2012 significantly lowered cholesterol by 43.56% in vitro compared to single strains and other compound ratios.Moreover, the compound probiotic exhibited a higher proliferation ability when galacto-oligosaccharide and stachyose were used as carbon sources, indicating a preference for these sources.This study can provide a reference for probiotic synergism and the development of functional food formulations.

Key words： probiotics; glucose-lowering and lipid-lowering activities; antagonistic analysis; compound probiotics; promotion of proliferation

参考文献

[1] MIR F A, ULLAH E, MALL R, et al.Dysregulated metabolic pathways in subjects with obesity and metabolic syndrome[J].International Journal of Molecular Sciences, 2022, 23(17):9821.
[2] HOU C Y, TAIN Y L, YU H R, et al.The effects of resveratrol in the treatment of metabolic syndrome[J].International Journal of Molecular Sciences, 2019, 20(3):535.
[3] LAZAREVIĆ S, »ANIĆ M, GOLOČORBIN-KON S, et al.Semisynthetic bile acids:A new therapeutic option for metabolic syndrome[J].Pharmacological Research, 2019, 146:104333.
[4] CREMON C, BARBARO M, VENTURA M, et al.Pre-and probiotic overview[J].Current Opinion in Pharmacology, 2018, 43:87-92.
[5] BEN-MILED H, BENOIT-BIANCAMANO M O, BEN-MAHREZ K, et al.Alpha-amylase and alpha-glucosidase inhibitory properties, beta-galactosidase activity, and probiotic potential of lactic acid bacteria and bifidobacteria from Apis mellifera intermissa and its products[J].World Journal of Microbiology & Biotechnology, 2023, 39(8):205.
[6] HAO J Y, ZHANG Y L, WU T, et al.The antidiabetic effects of Bifidobacterium longum subsp. longum BL21 through regulating gut microbiota structure in type 2 diabetic mice[J].Food & Function, 2022,13(19):9947-9958.
[7] SUN M Z, WU T, ZHANG G H, et al.Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism[J].Food & Function, 2020, 11(11):9514-9525.
[8] ZHANG Y L, WU T, LI W, et al.Lactobacillus casei LC89 exerts antidiabetic effects through regulating hepatic glucagon response and gut microbiota in type 2 diabetic mice[J].Food & Function, 2021,12(18):8288-8299.
[9] LIANG T T, XIE X Q, WU L, et al.Comparative analysis of the efficacies of probiotic supplementation and glucose-lowering drugs for the treatment of type 2 diabetes:A systematic review and meta-analysis[J].Frontiers in Nutrition, 2022, 9:825897.
[10] 贺珊珊, 鲍志宁, 林伟锋, 等.一种含有胆固醇胶束的培养基溶液的制备方法[P].中国:CN108795767A,2018-11-13.
HE S S, BAO Z N, LIN W F, et al.A preparation method of medium solution containing cholesterol micelles[P].China:CN108795767A,2018-11-13.
[11] WANG J J, TANG H, ZHANG C H, et al.Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice[J].The ISME Journal, 2015, 9(1):1-15.
[12] CHEN P, ZHANG Q X, DANG H, et al.Screening for potential new probiotic based on probiotic properties and α-glucosidase inhibitory activity[J].Food Control, 2014, 35(1):65-72.
[13] WON G, CHOI S I, PARK N, et al.In vitro antidiabetic, antioxidant activity, and probiotic activities of Lactiplantibacillus plantarum and Lacticaseibacillus paracasei strains[J].Current Microbiology, 2021, 78(8):3181-3191.
[14] DING W R, SHI C, CHEN M, et al.Screening for lactic acid bacteria in traditional fermented Tibetan yak milk and evaluating their probiotic and cholesterol-lowering potentials in rats fed a high-cholesterol diet[J].Journal of Functional Foods, 2017, 32:324-332.
[15] KUERMAN M, BAO Y H, GUO Y, et al.Effects of prebiotic carbohydrates on the growth promotion and cholesterol-lowering abilities of compound probiotics in vitro[J].LWT, 2020, 118:108703.
[16] HULIGERE S S, CHANDANA KUMARI V B, ALQADI T, et al.Isolation and characterization of lactic acid bacteria with potential probiotic activity and further investigation of their activity by α-amylase and α-glucosidase inhibitions of fermented batters[J].Frontiers in Microbiology, 2023, 13:1042263.
[17] AYYASH M, AL-NUAIMI A K, AL-MAHADIN S, et al.In vitro investigation of anticancer and ACE-inhibiting activity, α-amylase and α-glucosidase inhibition, and antioxidant activity of camel milk fermented with camel milk probiotic:A comparative study with fermented bovine milk[J].Food Chemistry, 2018, 239:588-597.
[18] SREEPATHI N, KUMARI V B C, HULIGERE S S, et al.Screening for potential novel probiotic Levilactobacillus brevis RAMULAB52 with antihyperglycemic property from fermented Carica papaya L[J].Frontiers in Microbiology, 2023, 14:1168102.
[19] MORRIS A.Microbial metabolite linked to T2DM[J].Nature Reviews.Endocrinology, 2018, 15(1):3.
[20] HERREMA H, NIESS J H.Intestinal microbial metabolites in human metabolism and type 2 diabetes[J].Diabetologia, 2020, 63(12):2533-2547.
[21] ROMERO-LUNA H E, PEREDO-LOVILLO A G, JIMÉNEZ-FERNÁNDEZ M.Probiotic and potentially probiotic bacteria with hypocholesterolemic properties[J].Food Reviews International, 2023, 39(2):689-707.
[22] ISHIMWE N, DALIRI E B, LEE B H, et al.The perspective on cholesterol-lowering mechanisms of probiotics[J].Molecular Nutrition & Food Research, 2015, 59(1):94-105.
[23] GREGOR A, AUERNIGG-HASELMAIER S, MALLEIER M, et al.Fiber consumption stimulates the activity of microbial bile salt hydrolases[J].Journal of Functional Foods, 2023, 107:105707.
[24] 韦云路, 刘义, 王瑶, 等.3株益生菌体外降胆固醇能力及体内降血脂效果评价[J].食品科学, 2017, 38(23):129-134.
WEI Y L, LIU Y, WANG Y, et al.Cholesterol-lowering ability in vitro and hypolipidemic effect in vivo of three probiotic strains[J].Food Science, 2017, 38(23):129-134.
[25] 崔华玲. 降胆固醇乳酸菌的筛选及其微胶囊化应用研究[D].广州:华南理工大学, 2022.
CUI H L.Screening of cholesterol-lowering lactic acid bacteria and its microencapsulation application[D].Guangzhou:South China University of Technology, 2022.
[26] KIM S J, PARK S H, SIN H S, et al.Hypocholesterolemic effects of probiotic mixture on diet-induced hypercholesterolemic rats[J].Nutrients, 2017, 9(3):293.
[27] LEI W P, LIU C G, PAN L N, et al.Screening of probiotic Lactobacilli with potential anti-allergic activity based on hyaluronidase inhibition and degranulation of RBL-2H3 cells in vitro[J].LWT, 2021,140:110707.
[28] 王芬, 刘鹭, 李函彤, 等.具有α-葡萄糖苷酶抑制作用益生菌的筛选及特性分析[J].食品科学, 2018, 39(16):192-200.
WANG F, LIU L, LI H T, et al.Screening for potential probiotics based on high α-glucosidase inhibitory activity[J].Food Science, 2018, 39(16):192-200.
[29] RAZA W, YUAN J, LING N, et al.Production of volatile organic compounds by an antagonistic strain Paenibacillus polymyxa WR-2 in the presence of root exudates and organic fertilizer and their antifungal activity against Fusarium oxysporum f.sp.niveum[J].Biological Control, 2015, 80:89-95.
[30] MOHANTY D, MISRA S, MOHAPATRA S, et al.Prebiotics and synbiotics:Recent concepts in nutrition[J].Food Bioscience, 2018, 26:152-160.
[31] 李雅丽, 王默涵, 周志桥.6种低聚糖对肠道益生菌生长情况的影响及代谢产物分析[J].食品科技, 2021, 46(3):7-13.
LI Y L, WANG M H, ZHOU Z Q.Effects of six oligosaccharides on the growth of intestinal probiotics and analysis of metabolites[J].Food Science and Technology, 2021, 46(3):7-13.
Options
文章导航

/

〈 〉

技术支持：北京玛格泰克科技发展有限公司